Cytek Biosciences, Inc.
CTKB
$4.81
$0.153.22%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -117.77% | -65.46% | -557.08% | -682.77% | 46.49% |
| Total Depreciation and Amortization | -0.10% | -2.46% | 11.02% | 8.94% | 20.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 82.00% | -19.48% | 994.97% | -66.47% | -42.36% |
| Change in Net Operating Assets | 634.01% | 197.06% | 36.82% | -209.33% | -109.68% |
| Cash from Operations | 1,165.74% | -2,088.80% | -138.61% | -129.48% | -98.26% |
| Capital Expenditure | -40.52% | -155.36% | -11.97% | 35.01% | -49.76% |
| Sale of Property, Plant, and Equipment | -86.96% | -81.82% | 2.09% | -95.24% | -69.74% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 162.15% | -342.67% | 98.34% | 232.10% | -595.47% |
| Cash from Investing | 142.78% | -386.49% | 97.10% | 219.68% | -911.72% |
| Total Debt Issued | -97.04% | 634.49% | -49.16% | 41,720.00% | 46,266.67% |
| Total Debt Repaid | -1,035.92% | 42.75% | -2,015.11% | -3.57% | -2.16% |
| Issuance of Common Stock | 22.82% | -46.15% | -36.41% | -6.80% | -37.69% |
| Repurchase of Common Stock | 96.01% | 97.78% | 96.71% | 98.83% | -64.71% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 68.72% | 134.48% | 66.32% | 116.06% | -52.07% |
| Foreign Exchange rate Adjustments | 165.80% | 152.61% | -6.98% | 189.71% | -140.72% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 141.26% | -630.93% | 96.18% | 214.06% | -325.92% |